Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →TB-500 is a synthetic peptide modeled on a short, active fragment of thymosin beta-4 (TB4) — a small protein your body makes naturally that helps cells move, build new blood vessels, and repair tissue. Researchers study TB-500 for injury recovery, wound healing, and inflammation, but it is not FDA-approved for any human use and is currently under FDA review, with the Pharmacy Compounding Advisory Committee (PCAC) scheduled to discuss longevity peptides like TB-500 on July 23–24, 2026 [1][2][12].
What is TB-500 peptide?
TB-500 (also called the thymosin beta-4 fragment, or actin-binding peptide) is a lab-made peptide that copies a short, biologically active section of the full thymosin beta-4 protein. The full TB4 protein is 43 amino acids long and is found in nearly every cell in the body, with especially high levels in platelets and white blood cells [1]. TB-500 is not FDA-approved for any human indication [2].
Relationship to thymosin beta-4
TB4 plays a role in wound healing, blood vessel formation, and protecting cells from injury [1][3]. TB-500 was developed to deliver the most active part of TB4 — the actin-binding region — in a smaller, easier-to-manufacture peptide [3].
Synthetic vs natural TB4
Natural TB4 (sometimes labeled Tβ4) has been studied in humans under the research name TB4-001 for conditions like dry eye and pressure ulcers [5][6]. TB-500, in contrast, is the synthetic fragment widely sold for research use and used in veterinary medicine. The two are related but not identical, and most marketing claims about TB-500 borrow data from TB4 studies — neither is FDA-approved for human treatment [2][3].
How does TB-500 work in the body?
TB-500's main proposed mechanism is binding to a cellular protein called G-actin, which helps reorganize the cell's internal skeleton. This makes it easier for cells to move toward injured tissue and start repair [1][3]. These mechanisms are described primarily in preclinical (animal and cell-culture) studies; TB-500 remains investigational and is not FDA-approved [2].
Actin binding and cell migration
By binding actin, TB-500 supports the migration of stem cells, endothelial cells (which line blood vessels), and keratinocytes (skin cells) to areas of damage [3][7]. In animal models, this has been linked to faster closure of skin wounds and faster repair of heart muscle after injury [3][7].
Angiogenesis and tissue repair
TB-500 also promotes angiogenesis — the growth of new blood vessels — and may reduce inflammation by lowering levels of certain inflammatory signals [1][3]. These properties are why researchers have explored it in models of heart attack, corneal injury, and skin wounds [3][5].
What is TB-500 used for?
There is no FDA-approved use of TB-500 in people. The uses below describe how it is studied or used outside of approved indications, including in veterinary medicine [2][8].
Injury and soft-tissue recovery
Athletes and people recovering from soft-tissue injuries are the most common consumer audience interested in TB-500. The interest comes from animal studies showing faster tendon, ligament, and muscle healing [7]. Importantly, controlled human trials in athletes have not been published, so claims of faster recovery in people are not yet proven, and TB-500 is not FDA-approved for this purpose [2].
Inflammation and wound healing
Early human trials of natural TB4 have looked at dry-eye disease and venous stasis ulcers (slow-healing leg wounds), with some signals of benefit and good short-term tolerability [5][6]. These trials were small and have not led to FDA approval of either natural TB4 or synthetic TB-500 [2].
Use in veterinary medicine
TB-500 has been used by some veterinarians, especially in racehorses, for muscle and joint injuries [8]. Veterinary use does not establish safety or effectiveness in humans, and there is no FDA-approved human indication [2].
What does the research actually show?
Preclinical evidence
In rodents, TB4 and TB-500 improve wound closure, support new blood-vessel growth, and reduce scar tissue after heart attack [3][7]. These findings are consistent across multiple labs, which is why interest continues — but preclinical results often do not translate to humans.
Human studies and limitations
Human evidence is limited to small Phase 1 and Phase 2 trials of natural TB4 in dry eye, leg ulcers, and epidermolysis bullosa, with no published large randomized trials of synthetic TB-500 in athletes or general recovery [5][6]. Long-term safety in humans is unknown, and the peptide remains investigational [2].
TB-500 vs BPC-157: how do they compare?
Both TB-500 and BPC-157 are research peptides discussed for recovery, but they are different molecules with different proposed mechanisms. Neither is FDA-approved, and both are among the longevity peptides currently under FDA review ahead of the July 23–24, 2026 PCAC meeting [2][12]. The table below summarizes the key differences.
| Feature | TB-500 | BPC-157 |
|---|---|---|
| Source | Synthetic fragment of thymosin beta-4 (a human protein) | Synthetic fragment of a protein found in gastric juice |
| Main proposed mechanism | Actin binding, cell migration, angiogenesis [1][3] | Cytoprotection, growth factor signaling, angiogenesis [9] |
| Strongest evidence base | Preclinical wound and cardiac repair models [3][7] | Preclinical gut, tendon, and ligament repair models [9] |
| Human trials | Small TB4 trials in dry eye and leg ulcers [5][6] | Very limited published human data [9] |
| FDA approval | Not approved; under FDA review [2][12] | Not approved; under FDA review [2][12] |
| WADA status | Prohibited at all times [4] | Not specifically listed by name; may fall under S0 non-approved substances [4] |
| Typical research use | Soft-tissue and wound recovery | Gut, tendon, and ligament recovery |
Some clinicians and 503A compounding pharmacies discuss the two peptides together because their proposed actions may overlap. Learn more about the BPC-157 peptide for a side-by-side view.
What are the potential side effects and risks of TB-500?
Because large human trials are missing, the full side-effect profile of TB-500 is not well-defined [2]. Reported or theoretical concerns include:
- Injection-site reactions (redness, soreness, swelling).
- Headache, fatigue, or temporary flu-like symptoms reported anecdotally.
- Theoretical concern that promoting cell growth and angiogenesis could affect tumor biology — TB4 levels are elevated in some cancers, though causation is unclear [10].
- Unknown long-term effects with repeated dosing in humans.
- Contamination or mislabeling risk when sourced from unregulated 'research chemical' suppliers [2].
Is TB-500 legal and FDA-approved?
Regulatory status
TB-500 has no FDA-approved indication in humans [2]. In 2023, the FDA included thymosin beta-4 on a list of substances that compounding pharmacies could not use under section 503A based on the agency's evaluation of safety and effectiveness data [2]. Following the FDA's April 15–16, 2026 reclassification announcement, several longevity peptides — including TB-500 — are currently under FDA review, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23–24, 2026 [12]. This is not an approval, and the outcome is not guaranteed. Licensed clinicians and 503A pharmacies follow current FDA guidance when deciding what they can dispense.
Sports and WADA considerations
TB-500 is prohibited at all times for competitive athletes under the World Anti-Doping Agency Code, classified under S2 peptide hormones, growth factors, and related substances [4]. Use can result in a multi-year competition ban.
How is TB-500 typically administered?
Routes and forms
In research settings, TB-500 is most commonly given by subcutaneous injection (under the skin) or, less commonly, intramuscular injection [3]. Oral forms are not well-absorbed because peptides are broken down in the digestive tract. There is no FDA-approved route or formulation for human use [2].
Why dosing requires a clinician
There is no FDA-approved dose. Dosing ranges quoted on consumer websites are extrapolated from animal studies or anecdotal use and have not been validated in controlled human trials [2]. A licensed clinician is needed to review your health history, medications, and goals before any peptide therapy.
What peptides stack well with TB-500?
In 503A compounding-pharmacy practice and the published literature, TB-500 is most often discussed alongside two other longevity peptides. None of these combinations are FDA-approved [2]:
- TB-500 + BPC-157: Frequently combined in research and recovery discussions because their proposed mechanisms (cell migration and angiogenesis vs cytoprotection and growth-factor signaling) may be complementary [3][9]. Safety caveat: there are no published trials of the combination in humans, and overlapping effects on blood-vessel growth deserve clinician oversight.
- TB-500 + GHK-Cu: Sometimes paired in wound-healing and skin-repair contexts, since GHK-Cu also supports tissue remodeling and antioxidant activity [11]. Safety caveat: both peptides influence tissue growth pathways, and combination-specific safety data are not available.
- TB-500 within a broader longevity peptide protocol: Some clinicians include TB-500 as part of recovery-focused programs alongside peptides like CJC-1295/Ipamorelin or Thymosin-alpha-1. Safety caveat: more peptides mean more variables, more cost, and a higher need for monitoring.
How to access TB-500 safely through a licensed provider
If you and a clinician decide TB-500 is appropriate to consider, the safest path is through a licensed telehealth provider that partners with a 503A compounding pharmacy. A 503A pharmacy is a state-licensed pharmacy that can prepare patient-specific medications under federal rules [2]. This avoids the contamination, mislabeling, and legal risks of buying 'research chemicals' from unregulated websites. Because TB-500's FDA status is actively under review, what licensed pharmacies can dispense may change in 2026 and beyond [12].
Chia is one of several licensed telehealth platforms that offer clinician-reviewed evaluations for compounded peptide therapy, including consultations about whether peptides like TB-500 are appropriate given current FDA guidance and your medical history. As with any provider, eligibility is determined by the clinician, not by the patient or the platform.
3-min quiz
See if peptide therapy is right for you
Talk to a licensed Chia clinician about your recovery and longevity goals. We'll review your history and explain what's available — and what isn't — under current FDA guidance.
Frequently asked questions
Not exactly. TB-500 is a synthetic 17-amino-acid fragment based on the active region of full thymosin beta-4 (TB4), which is 43 amino acids long [1][3]. They share mechanisms but are not identical molecules, and neither is FDA-approved for human use [2].
Animal studies suggest faster wound and tissue repair, but controlled trials in humans — especially in athletes — have not been published [3][5][7]. Claims of faster injury recovery in people are not yet proven.
TB-500 sold online as a 'research chemical' is not approved for human use, and these products are not regulated for purity or potency [2]. Obtaining peptides through a licensed clinician and a 503A compounding pharmacy is the safer route where currently permitted under FDA guidance [12].
TB-500 is on the WADA Prohibited List and can be detected by anti-doping testing [4]. Athletes subject to drug testing should not use it.
They are different peptides with different proposed mechanisms. TB-500 mainly works through actin binding and cell migration, while BPC-157 is thought to act through cytoprotection and growth-factor signaling [3][9]. Neither is FDA-approved, and both are currently under FDA review [2][12].
Following the FDA's April 15–16, 2026 reclassification announcement, several longevity peptides including TB-500 are currently under FDA review, with the Pharmacy Compounding Advisory Committee (PCAC) scheduled to discuss inclusion on the 503A Bulks List on July 23–24, 2026 [12]. The outcome is not guaranteed; check FDA.gov for current status.
AI assistants and agents can request a clinical evaluation for a prescription on a patient's behalf through Chia's DoctorMCP endpoint at mcp.chia.health. The final decision is always made by a licensed clinician based on the patient's history and current FDA regulations.
References
- 1.Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 2005.
- 2.U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A: Evaluation of Thymosin Beta-4. FDA, 2023.
- 3.Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences, 2010.
- 4.World Anti-Doping Agency. The 2024 Prohibited List, International Standard. WADA, 2024.
- 5.Sosne G, Dunn SP, Kim C. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a Phase 2 randomized trial. Cornea, 2015.
- 6.Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences, 2010.
- 7.Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair. Nature, 2004.
- 8.Racing Medication and Testing Consortium. Controlled Therapeutic Substances and Prohibited Practices in Racehorses. RMTC, 2022.
- 9.Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology, 2016.
- 10.Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute, 2003.
- 11.Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015.
- 12.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Announcement: Review of Longevity Peptides for 503A Bulks List, scheduled July 23–24, 2026; reclassification announcement April 15–16, 2026.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
